Clinical Trial Update: IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial (IGNITE) evaluating tirabrutinib against Rituximab/Temozolomide in relapsed/refractory primary central nervous system lymphoma.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Temozolomide (Temozolomide)
• Tirabrutinib (tirabrutinib)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Relapsed/Refractory Primary Central Nervous System Lymphoma | Phase 3 | Status: RECRUITING